NONSMALL CELL LUNG CANCER
Clinical trials for NONSMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NONSMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NONSMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy shows promise against lung cancer in major trial
Disease control CompletedThis phase 3 trial tested the immunotherapy drug cemiplimab against standard platinum-based chemotherapy in 712 patients with advanced or metastatic non-small cell lung cancer that has high PD-L1 levels. The study aimed to see if cemiplimab improves overall survival and delays ca…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Tailoring radiation by tumor genes: a tiny step toward smarter lung cancer treatment
Disease control CompletedThis small, completed study tested whether it is possible to personalize radiation doses for people with stage II or III non-small cell lung cancer based on the genetic profile of their tumor. Three participants received either standard or higher radiation doses depending on a ra…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Electric field therapy extends life in advanced lung cancer trial
Disease control CompletedThis phase 3 trial tested a portable device that creates electric fields to disrupt cancer cell division in 291 people with stage 4 non-small cell lung cancer that had worsened after initial chemotherapy. Participants wore the device on their chest while continuing standard treat…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC